Cerus (CERS) to Release Quarterly Earnings on Thursday

Cerus (NASDAQ:CERS) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Cerus to post earnings of ($0.01) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Cerus Price Performance

Shares of Cerus stock opened at $2.15 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.89 and a quick ratio of 1.29. The business has a 50 day simple moving average of $2.22 and a two-hundred day simple moving average of $1.72. The stock has a market capitalization of $412.99 million, a P/E ratio of -26.88 and a beta of 1.52. Cerus has a 12 month low of $1.12 and a 12 month high of $2.95.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. TD Cowen restated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Trading of Cerus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERS. Deutsche Bank AG lifted its holdings in Cerus by 8.4% during the 4th quarter. Deutsche Bank AG now owns 147,757 shares of the biotechnology company’s stock worth $304,000 after buying an additional 11,501 shares in the last quarter. Cerity Partners LLC grew its position in shares of Cerus by 17.4% during the fourth quarter. Cerity Partners LLC now owns 123,956 shares of the biotechnology company’s stock worth $255,000 after buying an additional 18,379 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Cerus by 373.5% during the fourth quarter. Franklin Resources Inc. now owns 149,427 shares of the biotechnology company’s stock worth $308,000 after buying an additional 117,868 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in Cerus in the third quarter valued at approximately $31,000. Finally, Voleon Capital Management LP purchased a new position in Cerus in the third quarter worth approximately $65,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.